BUCHYNSKYI MYCHAILO VASYLOVYCH
BUCHYNSKYI MYCHAILO VASYLOVYCH
Buchynskyi M, Kamyshna I, Halabitska I, et al. Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease. Front Microbiol. (Switzerland) - 2025;16. - Р1577724
Buchynskyi M., Kamyshna I., Halabitska I., Petakh P., Oksenych V., Kamyshnyi O. Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.//Journal of Personalized Medicine. -2025. - 15(4). -e156.
Buchynskyi M, Oksenych V, Kamyshna I, Vorobets I, Halabitska I, Kamyshnyi O. Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes. // Viruses (Basel) - 2024;16(6). - Р985.
Buchynskyi M., Oksenych V., Kamyshna I., Kamyshnyi O. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study. // Viruses.- 2024. -16(1). -е112
Buchynskyi. M., Kamyshna I., Oksenych V., Zavidniuk N., Kamyshnyi A. The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence //Viruses.- 2023.-15(5).-е 1072.
Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, Lyubomirskaya K, Kamyshna I, Potters G, Moshynets O. Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience.// Int J Mol Sci.- 2023.- 7;24(8).-е6887.
Buchynskyi M., Kamyshna I., Lyubomirskaya K., Moshynets O., Kobyliak N., Oksenych V., Kamyshnyi A. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. // Frontiers in immunology.-2023.- 14.- 1069-894.
Buchynskyi M, Oksenych V, Kamyshna I, Vari SG, Kamyshnyi A. Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis. // Viruses (Basel).-2023.-15(8).-P1724.
Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, Lyubomirskaya K, Kamyshna I, Potters G, Moshynets O. Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience. Int J Mol Sci (Basel).-2023.-24(8).-P6887.